| Dear Voornaam
Are you looking to develop your leadership skills? Cancer Research UK-funded junior postdocs can now join our leadership coaching programme and work with coaches in training.
During flexible one-on-one sessions, your coach helps you identify and work on specific goals, focusing on reflection and self-learning by asking thought-provoking questions. Coaching can help you manage new situations like balancing increased responsibilities or taking on a project.
The opportunity to work with a fully trained coach is available to senior postdocs, junior group leaders, established and senior researchers and those with leadership responsibilities. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
WERE INVESTING 123M IN SCOTLAND, BOLSTERING DISCOVERY SCIENCE Were awarding up to 123m over seven years to the Cancer Research UK Scotland Institute, (formerly known as the Beatson Institute) which will support around 300 researchers and 100 support staff across 30 research groups. The name change reflects the institutes success as a national centre of excellence.
This is our largest ever investment in Scotland and will support innovative discovery research themed around cellular metabolism in cancer and ways to target this for cancer therapy, the tumour microenvironment in metastasis and cancer reoccurrence and the biology of early disease to develop precision prevention' approaches.
The funding will support major studies into specific types of cancer which have a big impact on Scotlands population including liver, pancreatic, bowel and lung. |
|
|---|
|
|---|
|
|
OUR ANNUAL RESEARCH ACTIVITY In 2022/23, we invested 415m on new and ongoing cancer research programmes including 83m on basic research, 89m on research relevant to all types of cancer and 176m on specific cancer types.
We spent 18.7m on research specific to cancers that affect 024-year-olds; in the last four years weve nearly doubled our spend in this area making us the biggest charitable funder of research into childrens and young peoples cancers in the UK.
This means that were on track to spend 1.5bn on research over a five-year period as set out in our research strategy. |
|
|---|
|
|---|
|
|
 FREE RADNET WORKSHOP ON COMPLEX RESEARCH TECHNOLOGIES Are you looking to expand your knowledge on complex technologies to address radiation research questions?
Join our one-day workshop place on 17 November in Manchester and learn more about CRISPR, expression profiling (spatial transcriptomics, proteomics), complex modelling and computational approaches.
We welcome participation from basic discovery researchers, and clinical research fellows working in the field. |
|
|---|
|  TOP FIVE PRIORITIES FOR TRANSATLANTIC CANCER RESEARCH COLLABORATION Last week, the Medical Research Council (MRC) published a joint report from the virtual UK-US cancer summit that was convened by the MRC, the National Cancer Institute and us back in November 2021.
The discussions made a compelling case to unite local and international efforts in cancer research, and the ideas debated have now been consolidated into five key priorities.
These include identifying new cancer treatments and interventions faster, leveraging cancer data, delivering equitable cancer care, transforming how we prevent cancer and developing the cancer research workforce. |
|
|---|
|
|---|
|
|
METFORMIN IN LI FRAUMENI: FIRST PRECISION CANCER PREVENTION TRIAL AT OXFORD With our funding, Professor Sarah Blagden, head of the Oncology Clinical Trials Office at Oxford University, is working with the Oxford Primary Care Clinical Trials Unit to form the UKs first centre specialising in precision-prevention and early detection studies.
In the new teams first trial, theyre investigating whether the diabetes drug metformin could lower cancer risk levels in people with Li Fraumeni syndrome, a condition that runs in families and brings a lifetime cancer risk of more than 90%.
We're turning the whole idea of prevention trials on its head, says Blagden. We're really focusing in on very high-risk patients who can give us a better insight into the biology of cancer. And theyre the ones who are most motivated to contribute they want an intervention more than anyone else. |
|
|---|
|
|---|
|
|
 USING GENERATIVE AI TOOLS IN RESEARCH Weve agreed a joint statement, with other UK funders around the use of generative AI tools in funding applications.
We expect any researchers using generative AI tools in their funding applications to act responsibly and transparently. And to protect confidentiality and research integrity, peer reviewers wont be permitted to use generative AI tools in any way during the peer review or critique process.
Weve also published some general guidance for researchers around the responsible use of these tools. |
|
|---|
|  CORINNE FAIVRE-FINN: HOW RAPID RT COULD IMPROVE LUNG CANCER SURVIVAL What we have demonstrated with our research in Manchester is that patients who have lung cancer often already have heart conditions, and the impact [of radiotherapy] on the heart is much earlier.
In the fourth episode of the podcast series Lung Cancer: From basic biology to transformative therapies, Corinne Faivre-Finn from the University of Manchester talks about the RAPID-RT clinical trials launched at The Christie early this year.
Hear from Corinne on how the trial could improve survival rates for lung cancer patients, and how AI is involved to benefit its data collection. |
|
|---|
|
|---|
|
|
| | | Paris, France 04 October 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
| | | Liverpool, UK 18 October 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 20 October 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 03 November 2023 |
|
|---|
|
|---|
| | | Edinburgh, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
